Mouse Von Willebrand Factor 2 Antibody Pair - BSA and Azide free (RMAB-0252311)
Cat. No.: RMAB-0252311
Category: Antibody Pair
INQUIRY
10 x 96 tests
The Antibody Pair can be used to quantify Mouse von Willebrand Factor A2. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/mL as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results._x000D_
Product Features
| Conjugate | Unconjugated capture and detector antibodies |
|---|---|
| Species Reactivity | Mouse |
| Range | 62.5 pg/mL - 4000 pg/mL |
| Applications | Sandwich ELISA |
| Key Features | Unconjugated capture and detector antibodies; Adaptable to any antibody pair-based assay format; Antibody concentration ~ 1 mg/mL; BSA and azide free buffer - ready for conjugation; Reacts with: Mouse |
Target Information
| Target Symbol | VWF |
|---|---|
| Target Name | von Willebrand factor |
| UniProt ID | P04275 |
| Cellular Localization | Secreted. Secreted > extracellular space > extracellular matrix. Localized to storage granules. |
| Function | Important in the maintenance of hemostasis, it promotes adhesion of platelets to the sites of vascular injury by forming a molecular bridge between sub-endothelial collagen matrix and platelet-surface receptor complex GPIb-IX-V. Also acts as a chaperone for coagulation factor VIII, delivering it to the site of injury, stabilizing its heterodimeric structure and protecting it from premature clearance from plasma. |
| Involvement in Disease | Defects in VWF are the cause of von Willebrand disease (VWD). VWD defines a group of hemorrhagic disorders in which the von Willebrand factor is either quantitatively or qualitatively resulting in altered platelet function. Symptoms vary depending on severity and disease type but may include prolonged bleeding time, deficiency of factor VIII and impaired platelet adhesion. Type I von Willebrand disease is the most common form and is characterized by partial quantitative plasmatic deficiency of an otherwise structurally and functionally normal Willebrand factor; type II is associated with a qualitative deficiency and functional anomalies of the Willebrand factor; type III is the most severe form and is characterized by total or near-totalof Willebrand factor in the plasma and cellular compartments, also leading to a profound deficiency of plasmatic factor VIII. |
| Post-translational Modifications | All cysteine residues are involved in intrachain or interchain disulfide bonds. N- and O-glycosylated. |
| Domain | The von Willebrand antigen 2 is required for multimerization of vWF and for its targeting to storage granules. |
| Sequence Similarities | Contains 1 CTCK (C-terminal cystine knot-like) domain. Contains 4 TIL (trypsin inhibitory-like) domains. Contains 3 VWFA domains. Contains 3 VWFC domains. Contains 4 VWFD domains. |
Storage & Shipping
| Storage & Shipping | Store at 4°C. Please refer to protocols. |
|---|
For research use only. Not for clinical use.
